Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2018 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Total Non-Current Liabilities of $600.2 million for Q1 2026, up 35.45% year-over-year from $443.1 million in Q1 2025, and up 13.64% quarter-over-quarter from $528.1 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $600.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 35.45% year-over-year to $600.2 million; the TTM figure through Mar 2026 stood at $600.2 million (up 35.45% YoY), while the FY2025 annual figure was $528.1 million, up 19.32% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $600.2 million, up from $528.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $600.2 million in Q1 2026, with the low at $36.3 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $413.1 million (2024), against an average of $355.3 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 68.09% in 2022, then surged 569.02% in 2023.
- Mirum Pharmaceuticals' Total Non-Current Liabilities stood at $206.3 million in 2022, then surged by 91.0% to $394.1 million in 2023, then grew by 12.31% to $442.6 million in 2024, then increased by 19.32% to $528.1 million in 2025, then increased by 13.64% to $600.2 million in 2026.
- Business Quant data shows MIRM's Total Non-Current Liabilities at $600.2 million in Q1 2026, $528.1 million in Q4 2025, and $477.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | 994.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 994.25 Mn |
| Mar 31, 2026 | 600.17 Mn |
| Dec 31, 2025 | 528.12 Mn |
| Sep 30, 2025 | 477.09 Mn |
| Jun 30, 2025 | 461.61 Mn |
| Mar 31, 2025 | 443.09 Mn |
| Dec 31, 2024 | 442.61 Mn |
| Sep 30, 2024 | 431.90 Mn |
| Jun 30, 2024 | 427.79 Mn |
| Mar 31, 2024 | 413.07 Mn |
| Dec 31, 2023 | 394.10 Mn |
| Sep 30, 2023 | 381.56 Mn |
| Jun 30, 2023 | 364.98 Mn |
| Mar 31, 2023 | 191.29 Mn |
| Dec 31, 2022 | 206.34 Mn |
| Sep 30, 2022 | 57.03 Mn |
| Jun 30, 2022 | 182.41 Mn |
| Mar 31, 2022 | 36.28 Mn |
| Dec 31, 2021 | 172.44 Mn |
| Sep 30, 2021 | 178.75 Mn |